AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03695692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pelvic floor exercise and connective tissue massage
Description: Pelvic floor exercises with connective tissue massage will be performed.The massage program is carried out for 18 sessions, 3 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
Study NCT03695692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pelvic floor exercise
Description: The exercise program is performed every day for 6 weeks
Study NCT03527017 — intervention group
Intervention type: OTHER
Intervention: Survey on Use of Tobacco Products in the General Population
Description: Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Germany.
Study NCT03527017 — intervention group
Intervention type: OTHER
Intervention: Survey on Use of Tobacco Products in IQOS Users
Description: Online survey to describe patterns of use in adult IQOS users residing in Germany.
Study NCT02062489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg(2#)/day, PO, daily
Study NCT02593929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Study NCT04287530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Poly-unsaturated fatty acids supplementation
Description: Daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
Study NCT02062489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2#/day, PO, daily
Study NCT00875550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Study drug titrated up or down to maintain target UMSS range.
Study NCT00875550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Rescue medication for sedation according to UMSS scores
Study NCT00875550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Rescue medication for pain based on UMSS scores
Study NCT00875550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Rescue medication for pain based on UMSS scores.
Study NCT02334722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Study NCT02334722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Study NCT00002601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 ug/kg daily following stem cell reinfusion
Study NCT00002601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Course 2 - 100 mg/m2 at an infusion rate of 25 mg/hr
Study NCT00002601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Course 1 - 150 mg/m2 by continuous intravenous infusion for 96 hours.
Study NCT00002601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Course 1 - 14 gm/M2 by continuous intravenous infusion for 96 hours.
Study NCT00002601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Course 2 - 75 mg/m2 infused at a rate of 5 mg/minute
Study NCT00002601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Administered on Day 0 following high-dose chemotherapy in both courses 1 and 2
Study NCT02365012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Crossover intervention comparing midodrine to placebo for subjects with orthostatic intolerance
Study NCT04298918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive oral placebo in combination with trastuzumab emtansine.
Study NCT04298918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive oral venetoclax.
Study NCT04287530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological intervention
Description: Rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session.
Study NCT04287530 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological intervention
Description: Rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session.
Study NCT04287530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
Study NCT04287530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
Study NCT04039139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Body Intervention 1: Mind-Body-Syndrome-Therapy (MBST)
Description: Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
Study NCT04039139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind Body Intervention 2
Description: Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
Study NCT02451956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
Study NCT04298918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Participants will receive intravenous (IV) trastuzumab emtansine.
Study NCT02451956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
Study NCT03265587 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00849550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)
Description: bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral
Study NCT04693871 — intervention group
Intervention type: DEVICE
Intervention: Transesophageal ultrasound
Description: Patients with nonvalvular atrial fibrillation underwent radiofrequency ablation combined with left atrial appendage closure and recovered to sinus rhythm after the operation. To study the changes of left atrial organization and function of two groups of patients with different left atrial appendage emptying speeds.
Study NCT03607370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery after 12 weeks of delay after chemoradiotherapy.
Description: Surgery consists oncologic resection of the rectal cancer with total excision of the mesorectum after 12 weeks of delay after the end of chemoradiotherapy.
Study NCT03335501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: The participant's insulin pump will be used to infuse insulin
Study NCT03335501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system
Description: The Dexcom G4 Platinum will be used to measure glucose levels
Study NCT03335501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 11-hour intervention with the single-hormone artificial pancreas
Description: Subjects will be admitted at IRCM at 9:30. An intravenous catheter will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing rapid-acting Aspart or faster acting Aspart will be placed in the insulin pump. Closed-loop strategy will start at 10:00 until 21:00. A glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pumps' parameters will then be changed manually to implement the computer generated recommendations.~At 12:00, a lunch meal will be served. An insulin bolus will be given 15 minutes before the meal. At 17:00, a dinner meal will be served. As recommended, an insulin bolus will be given at the time of the meal. Each subject will ingest the same meals during both visits.~Venous blood samples will be obtained for the measurement of plasma glucose and insulin concentrations. Blood samples will be taken every 20 minutes.
Study NCT00613522 — intervention group
Intervention type: OTHER
Intervention: polygraphic study
Description: Berlin scale will be measured. A polygraphic study will be performed to subjects with a Berlin scale > 2.~Patients stroke characteristics will be recorded (initial severity, stroke mechanism) at baseline and stroke outcome will be evaluated at 3 months (stroke recurrence and functional outcome).~Controls will be evaluated at 3 months using a phone interview
Study NCT04383574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (600SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
Study NCT04383574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of high dosage (1200SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (1200SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
Study NCT01864226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5545965
Description: Multiple ascending doses
Study NCT04383574 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0,28
Description: The placebo was manufactured by Sinovac Research \& Development Co., Ltd., Two doses of placebo at the schedule of day 0,28,and one dose of booster immunization with placebo 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
Study NCT04383574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of low dosage (300SU/0.5ml)experimental vaccine at the schedule of day 0,28,and one dose of booster immunization with low dosage (300SU/0.5ml) experimental vaccine 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
Study NCT03593512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Bilateral deep brain stimulation of the pedunculopontine nucleus
Study NCT03421717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan brush
Description: If inflammation (Bleeding on probing) and deep pockets (4 mm or more) is present at the control - maintenance is performed according to allocation
Study NCT03421717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan brush
Description: If inflammation (Bleeding on probing) and deep pockets (4 mm or more) is present at the control - maintenance is performed according to allocation
Study NCT00520988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of telephone-based Interactive Voice Recognition system
Description: Use of telephone-based Interactive Voice Recognition system, for reporting of health information and blood pressure measurements
Study NCT03137251 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS 1
Description: A portable TENS unit will be used by the principal investigator to apply the experimental intervention. Two pairs of electrodes measuring 5 x 9 cm will be fixed on the paravertebral regions of the participants of the experimental group using hypoallergenic surgical tape. Two paired electrodes will be placed 1 cm laterally on either side of the spine at the T10 to L1 and S2 to S4 levels.
Study NCT03137251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 1
Description: A portable TENS unit will be used by the principal investigator to apply the experimental intervention. Two pairs of electrodes measuring 5 x 9 cm will be fixed on the paravertebral regions of the participants of the experimental group using hypoallergenic surgical tape. Two paired electrodes will be placed 1 cm laterally on either side of the spine at the T10 to L1 and S2 to S4 levels.
Study NCT03137251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 2
Description: An intervention similar to arm 1 will be performed but with different doses.
Study NCT03137251 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo TENS
Description: An intervention similar to arm 1and 2 will be performed but,in this case, it is a sham device.
Study NCT03137251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo TENS
Description: An intervention similar to arm 1and 2 will be performed but,in this case, it is a sham device.
Study NCT05978726 — intervention group
Intervention type: DRUG
Intervention: Dual antiplatelet therapy with aspirin and either ticagrelor or clopidogrel
Description: Patients with acute myocardial infarction randomly received dual antiplatelet therapy with with aspirin 100mg daily and either ticagrelor 90mg twice daily or clopidogrel 75mg once daily for at least 9 months after PCI as needed.
Study NCT01528462 — intervention group
Intervention type: OTHER
Intervention: Expedited Treatment of Sleep Disorders
Description: Patients in this arm will undergo an expedited polysomnogram (if clinically necessary) and early treatment of any sleep disorders. Sleep-related disorders will be managed with the currently recommended therapies; patients with obstructive sleep apnea will be treated with positional therapy, continuous positive airway pressure (CPAP), etc., and those with restless legs syndrome will be treated with standard treatments such as iron, or dopaminergic agonists. Patients will also be counselled on improving their sleep hygiene and adjusting the timing of their medication administration to optimize efficacy. Furthermore, patients will receive information handouts.
Study NCT00573417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: modafinil 100mg tablets. dose excalation up to 300mg
Study NCT00573417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02900209 — intervention group
Intervention type: OTHER
Intervention: Influenza Vaccination
Study NCT01864226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Multiple ascending doses
Study NCT00652418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
Description: Magnevist at a dose of 0.1 mmol/kg
Study NCT00652418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
Description: Magnevist at a dose of 0.2 mmol/kg
Study NCT03202459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A - gabapentin 600 mg
Description: The patient will receive oral 600 mg gabapentin 2 h before surgery
Study NCT03202459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B - pregabalin
Description: The patient will receive oral pregabalin 150 mg 2 h before surgery
Study NCT03202459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group C - placebo
Description: The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
Study NCT01097577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 1 capsule (75 mg) by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
Study NCT01097577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
Study NCT04877925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard chest tubes
Description: 2 standard postoperative chest tube used
Study NCT04877925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coaxial chest tube
Description: 1 postoperative smart drain coaxial tube
Study NCT03329183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: High-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
Study NCT01985139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based tasks
Description: Computer-based tasks designed to assess size and time discrimination capacities
Study NCT01985139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood drawn for the measurement of circulating endocannabinoids concentrations
Study NCT02185742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Based Case Management
Study NCT02403661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post surgical electrical stimulation
Description: Post surgical electrical stimulation immediately after surgical nerve repair
Study NCT02403661 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Post surgical electrical stimulation
Description: Post surgical electrical stimulation immediately after surgical nerve repair
Study NCT00706576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion of opioid growth factor
Description: Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
Study NCT02019537 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Steroid injection into the subacromial space
Description: * Group: Steroid~* Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~* The number of injections : only once during the study period~* Injection site : subacromial space~* Material : 25-gauze spinal needle~* Subacromial injections were performed using ultrasonographic guidance.
Study NCT02019537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic PRP injection into the subacromial space
Description: * Group: Allogeneic PRP~* Total volume of injection drugs: 4ml~* The number of injections : only once during the study period~* Injection site : subacromial space~* Material : 25-gauze spinal needle~* Subacromial injections were performed using ultrasonographic guidance.
Study NCT01354418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl Extended Release
Description: One phenylephrine HCl 30 mg extended release tablet orally
Study NCT01354418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine HCl Immediate Release
Description: One phenylephrine HCl 10 mg immediate release tablet every 4 hours for three doses
Study NCT01194791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 15 mg by mouth for 21 days followed by 7 days rest during 6 cycles
Study NCT01194791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cycles
Study NCT01194791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral dexamethasone 20 mg/day on days 1-4 and 9-12 given at 4-week intervals during 6 cycles
Study NCT04666116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation in patients with covid disease admitted to hospital
Description: Dietary supplementation in patients with covid disease admitted to hospital
Study NCT01249651 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: esomeprazole 40 mg
Description: esomeprazole 40 mg once daily, 8 weeks
Study NCT03115177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision for total shoulder arthroplasty.
Study NCT03115177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin